期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 12, 期 4, 页码 369-377出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2016.1144473
关键词
sublingual immunotherapy; SLIT-tablet; allergic rhinitis; House dust mite; allergy immunotherapy
类别
资金
- ALK-Abello, Denmark
- Allergopharma, Germany
- Artu-Biologicals, Netherlands
- Bencard, Great Britain
- Bionorica, Germany
- Biomay, Austria
- Cytos, Switzerland
- HAL, Netherlands
- Hartington, Spain
- GSK, Great Britain
- Leti, Spain
- Lofarma, Italy
- Novartis, Switzerland
- Roxall, Germany
- Boehringer Ingelheim, Germany
- MEDA Pharma, Germany
- MSD, USA
- Phadia/Thermofisher, Sweden
- Optima, Germany
- Bencard, Germany
- Novartis, Austria
- Stallergenes, Austria
- Thermo Fisher Scientific
- Allergopharma
- Allergy Therapeutics
- Biomay
- Calistoga
- GSK
- HAL
- MSD
- Ono
- Oxagen
- RespiVert
- Stallergenes
- VentirX
- Sigmapharm
- SQ HDM SLIT-tablet
House dust mite (HDM) allergy represents a highly prevalent inhalant allergy, and exposure to HDM allergens results in allergic rhinitis with persistent symptoms that may not be adequately controlled with available allergy pharmacotherapy. Allergy immunotherapy constitutes a complementary treatment option targeting the underlying immunological mechanisms of allergic disease and represents the only treatment with a potential for disease modification and long-term efficacy. As traditional allergy immunotherapy delivered by subcutaneous injection of specific HDM allergens involves a time-consuming treatment regimen and a risk of systemic adverse reactions, sublingually administered allergy immunotherapy (SLIT) has been investigated as a more convenient treatment option with similar levels of efficacy and an improved safety profile that allows for at-home daily administration. In this Drug Profile, we provide a review of the clinical data behind the SQ HDM SLIT-tablet, which was recently approved for the treatment of HDM-induced allergic rhinitis by regulatory authorities in Europe and Japan.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据